NEW JERSEY TUBERCULOSIS CASE, SUSPECT AND STATUS REPORT SHADED AREAS ARE FOR STATE USE ONLY; LEAVE BLANK.

Similar documents
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention

Recent Advances in The Treatment of Mycobacterium Tuberculosis

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

Self-Study Modules on Tuberculosis

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016

Tuberculosis in Children and Adolescents

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California

Management of Tuberculosis: Indian Guidelines

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, Frequently Asked Questions

Chapter 5 Treatment for Latent Tuberculosis Infection

Appendix B: Provincial Case Definitions for Reportable Diseases

Chapter 6 Treatment of Tuberculosis Disease

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

Self-Study Modules on Tuberculosis

Use of Nucleic Acid Amplification Tests in TB patients in California

Pediatric Latent TB Diagnosis and Treatment

Pregnancy and Tuberculosis. Information for clinicians

There are 5 demographic data elements that include gender, date of birth, race, ethnicity status,

New Jersey Department of Health and Senior Services. Standards of Care for Tuberculosis Disease and Latent TB Infection

Elisabeth Patton, DVM, PhD, Diplomate ACVIM

New York City Department of Health Protocols for Latent TB Infection Treatment

Clinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4

Hawaii Administrative Rules. Title 11. Department of Health. Chapter 164. Tuberculosis

MANAGEMENT OF TUBERCULOSIS

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, November 2015

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Chapter 8 Community Tuberculosis Control

DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS)

Tuberculosis: FAQs. What is the difference between latent TB infection and TB disease?

PEOSH Model Tuberculosis Infection Control Program

Massachusetts Tuberculosis Nursing Case Management Protocols. Tuberculosis Elimination Achieved through Management

Tuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions

Clinical Scenarios In Childhood TB. Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C

12 Points of Tuberculosis (TB) Patient Education

NOTICE OF PUBLIC HEARING REGARDING PROPOSED CHANGES IN HEALTH CARE SERVICES PROVIDED BY FRESNO COUNTY

Regulations for Tuberculosis Control in Minnesota Health Care Settings

Chapter Four: Treatment of Tuberculosis Disease

3. Blood and blood products such as serum, plasma, and other blood components.

Table. Positive Purified Protein Derivative Results (Pediatrics In Review Apr 2008)

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

Treatment of Tuberculosis

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit

LEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015

2011 NTP Paediatric guidelines update- final draft

Personal Data Form (PDF)

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

Your appointment is scheduled for at with Dr. Your arrival time is.

Tuberculosis Policy and Procedure Manual 2014

Treatment of Patients with Drug Addiction and Tuberculosis: New Strategies for the Future Directions

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Assisted Living - TB Risk Assessment

Department of State Academic Exchanges Participant Medical History and Examination Form

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Viral Hepatitis Case Report

CERTIFIED NURSING ASSISTANT PROGRAM

Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children

Tuberculosis Prevention and Control Protocol, 2008

Collection: Hispanic or Latino OR Not Hispanic or Latino. Second, individuals are asked to indicate one or more races that apply among the following:

Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014)

Massachusetts Application for Health and Dental Coverage and Help Paying Costs

Colonoscopy Data Collection Form

Long-term Care - TB Risk Assessment

TUBERCULOSIS (TB) CASE MANAGEMENT/TEAM APPROACH. I. TITLE: Protocol for the case management of persons with suspected or confirmed active TB disease.

Guideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0

Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA. Minoo Ghajar Orange County Public Health Laboratory

Place of Service Codes for Professional Claims Database (updated November 1, 2012)

DANVILLE-PITTSYLVANIA COMMUNITY SERVICES 245 HAIRSTON STREET DANVILLE, VIRGINIA

X-Plain Pediatric Tuberculosis Reference Summary

Tuberculosis and You A Guide to Tuberculosis Treatment and Services

Place of Service Codes for Professional Claims Database (updated August 6, 2015)

Last Name First M.I. Date. Street Address Apartment/Unit # License Number: License Expiration Date:

Nevada State Health Division Technical Bulletin

Instructions for Completing the CMS 1500 Claim Form

Policy Holder Name Relationship to Patient SSN DOB

REGISTRATION FORM. How would you like to receive health information? Electronic Paper In Person. Daytime Phone Preferred.

Enclosed you will find the necessary paperwork that must be completed and returned to Continuing Education prior to the start of the program.

Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department

Questions and Answers About Tuberculosis

Tuberculosis Case Management in Prisoners

Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Application for Employment

San Francisco Treatment Guidelines for Latent Tuberculosis Infection

IMA Knowledge June, 2015

Management of Tuberculosis (TB)

TB preventive therapy in children. Introduction

Nephrology Consultants of Georgia, P.C.

Emerging Infectious Disease (4): Drug-Resistant Tuberculosis

How To Identify A Substance Abuse/Addiction Counselor

Healthy Living Clinic, LLC Phone:(321) / FAX:(321)

CDHS/CTCA JOINT GUIDELINES Guidelines for the Treatment of Active Tuberculosis Disease. Table of Contents

Patient Education CONTENTS. Introduction

LTBI Program Implementation in a Substance Abuse Treatment Facility

Age In London TB is more common in younger adults aged years and peaks in the age group (3).

Application for Enrollment Dental Assistant Program

FAMILY CONTACT INFORMATION

Real-Time Surveillance for Tuberculosis Using Electronic Health Record Data from an Ambulatory Practice in Eastern Massachusetts

Transcription:

SHADED AREAS ARE FOR STATE USE ONLY; LEAVE BLANK. Type of Report: Initial Recurrence Current Status Patient s Name (Last, First, MI) 4. Street Address: (Check if New ) Within City Limits: Yes No County: City: State: Zip : Municipal : 1. Date Reported () 3. CASE NUMBERS: Year Identification Reported State Number REASON: STATE CASE NO.: 2. Date Submitted Month Day Year LINKING CASE NO.: LINKING CASE NO.: 5. Count Status: (select one) Count as a TB case Noncountable TB Case Suspect Counted by another US area TB treatment initiated in another country Recurrent TB within 12 months after completion of therapy 6. Date Counted: Month Day Year 7. Previous Diagnosis of TB Disease: (select one) Yes No If YES, enter year of previous TB Diagnosis: 11. Ethnicity: Hispanic or Latino Not Hispanic or Latino 8. Date of Birth: 9. Sex at Birth Male Female 10. Race: (select all that apply) American Indian or Alaska Native Asian: (specify) Black or African American Native Hawaiian or other Pacific Islander: Specify White 12. Country of Birth: U.S. Born (or born abroad to a parent who was a U.S. Citizen: (select one) Yes No Country of Birth: 13. Month-Year Arrived in US: - 14. Pediatric TB Patients (<15 years old): Country of birth for primary Guardian(s): (specify) Guardian 1: Guardian 2: Patient lived outside the U.S. for >2 months? Yes No Unknown If Yes, list countries (specify): 15. Status at TB Diagnosis (select one) Alive Dead If Dead, enter date of death: If Dead, was TB the cause of Death? Yes No Unknown 16. Site of TB Disease (select all that apply) Pulmonary Bone and/or Joint Pleural Genitourinary Lymphatic: Cervical Meningeal Lymphatic: Intrathoracic Peritoneal Lymphatic: Axillary Site not stated Lymphatic: Other Laryngeal Lymphatic: Unknown Other (Specify): (state use only) 1 2 3 SEP 15 Page 1

17. Sputum Smear: (select one) 18. Sputum Culture: (select one) Date Reported: Laboratory (specify): 19. Smear/Pathology/Cytology of Tissue and Other Body Fluids: (select one) Type of Exam (select all that apply): Smear Pathology/Cytology 20. Culture of Tissue and Other Body Fluids: (select one) Date Reported: Lab: 21. Nucleic Acid Amplification Test Result: (select one) Date Result Reported: Indeterminate Enter specimen type: Laboratory (specify): Sputum OR if not sputum, specify: 17a. Sputum Smear: (select one) 18a. Sputum Culture: (select one) Date Reported: Laboratory (specify): 19. Smear/Pathology/Cytology of Tissue and Other Body Fluids: (select one) Type of Exam (select all that apply): Smear Pathology/Cytology 20a. Culture of Tissue and Other Body Fluids: (select one): Date Reported: Lab: 22. Chest Radiograph and Other Chest Imaging Study 22A. Initial Chest Radiograph: Date: (select one) Normal Abnormal * Not Done Unknown * For ABNORMAL Initial Chest Radiograph: Evidence of a cavity? (select one) Yes No Unknown Consistent with TB? (select one) Yes No Unknown Evidence of miliary TB? (select one) Yes No Unknown 22B. Initial Chest CT Scan or Other Chest Imaging Study: Date: (select one) Normal Abnormal * Not Done Unknown * For ABNORMAL Initial Study: Evidence of a cavity? (select one) Yes No Unknown Consistent with TB? (select one) Yes No Unknown Evidence of miliary TB? (select one) Yes No Unknown 22C. Follow up Chest Radiograph, CT Scan or Other Chest Imaging Study: Date: Chest (select one) Improved Worsening Stable CT Scan Other (specify): 23.Tuberculin (Mantoux) Skin Test at Diagnosis: (select one) Positive Not Done Date Test Placed: Millimeters Induration: 24. Interferon Gamma Release Assay for Mycobacterium Tuberculosis at Diagnosis: (select one) Date Collected: Positive Not Done Indeterminate Test Type (specify): 25. Primary Reason Evaluated for TB Disease (select one) TB Symptoms Abnormal Chest Radiograph (incidental) Contact Investigation Targeted Testing Health Care Worker Employment/Administrative Testing Immigration Medical Exam Incidental Lab Result Unknown SEP 15 Page 2

26. HIV Status at Time of Diagnosis: (select one) Negative Indeterminate Not Offered Unknown Positive Refused Test Done Results Unknown State Patient Number: 27. Homeless Within The Past Year? (select one) No Yes Unknown 28. Resident of Correctional Facility at Time of Diagnosis? (select one) If Yes: (select one) Federal Prison Local Jail Other Correctional Facility If Yes, under the custody of Immigration and State Prison Juvenile Correctional Facility Unknown Customs Enforcement? Name of Facility: No Yes 29. Resident of Long-Term Care Facility at Time of Diagnosis? (select one) If Yes: (select one) Nursing Home Residential Facility Alcohol or Drug Treatment Facility Unknown Hospital-based Facility Mental Health Residential Facility Other Long Term Care Facility Name of Facility: 30. Primary Occupation Within the Past Year (select one) Health Care Worker Migrant/Seasonal Worker Retired Not Seeking Employment (e.g. student, homemaker, disabled) Correctional Facility Employee Unemployed Unknown Other (specify): 31. Injecting Drug Use Within Past Year (select one) 32. Non-Injecting Drug Use Within Past Year (select one) 33. Excess Alcohol Use Within Past Year (select one) 34. Additional TB Risk Factors (select all that apply) Contact of MDR-TB Patient Incomplete LTBI Treatment Diabetes Mellitus Other (Specify) (2 years or less) Contact of Infectious TB Patient TNF-a Antagonist Therapy End Stage Renal Disease None (2 years or less) Missed Contact (2 years or less) Post-organ Transplantation Immunosuppression (not HIV/AIDS) 35. Immigration Status at First Entry to the U.S. (select one) Immigrant Visa Tourist Visa Asylee or Parolee Student Visa Family Fiancé Visa Other Immigration Status Not Applicable Employment Visa Refugee Unknown * U.S. Born (or born abroad to a parent that was a U.S. Citizen) * Born in one of the U.S. Territories, U.S. Island Areas or U.S. Outlying Areas 36. Initial Therapy Started 36a. Current Therapy * 37. Initial Drug Regimen 37A. Current Drug Regimen mg mg mg Isoniazid Ethionamide Moxifloxacin Rifampin Amikacin Cycloserine Pyrazinamide Kanamycin Para-Amino Ethambutol Capreomycin Salicylic Acid Streptomycin Ciprofloxacin Other mg Rifabutin Levofloxacin Other mg Rifapentine Ofloxacin Patient s Weight: lbs. kg. *Please document current drug regimen changes and discontinued medications SEP 15 Page 3

UD7. Hospitalization Hospital Medical Record #: Admission Date: Discharge Date: I. Diagnosing Physician City: II. Other Physician City: III. Case Manager UD8. Supervision is NOW being provided by City: Report Prepared By State: State: Health Dept. Private/Hospital/Hosp. Clinic/Institution Both HD and Private State: Date: Remarks: Signature: (not legal unless signed) SEP 15 Page 4

Follow up 1 38. Genotyping Accession Number Isolate submitted for genotyping? Yes No If YES, genotyping Accession Number for episode: 39. Initial Drug Susceptibility Testing: Was drug susceptibility testing done? (select one) Date first isolate collected for which drug susceptibility was done: Enter specimen type: Sputum OR if not sputum: Specify Source: 40. Drug Susceptibility Results (select one) 39a. Other Drug Susceptibility Testing: Was drug susceptibility testing done? (select one) Date first isolate collected for which drug susceptibility was done: Enter specimen type: Sputum OR if not sputum: Specify Source: Initial Other (Select one option for each drug checked) Isoniazid Capreomycin Rifampin Ciprofloxacin Pyrazinamide Levofloxacin Ethambutol Ofloxacin Streptomycin Moxifloxacin Rifabutin Other Quinolones Rifapentine Cycloserine Ethionamide PAS Amikacin Gatifloxacin Kanamycin Other drug Other drug Specify Lab: 41.Sputum Culture Conversion Documented (select one) If yes, enter date specimen collected for FIRST consistently negative sputum culture: 42. Moved (Must Include Address) Did the patient move during TB therapy: No Yes If YES, moved to where: (select all that apply) If no, enter reason for not documenting sputum culture conversion: (select one) Follow up 2 Clinically Improved Patient refused Patient lost to follow up No follow-up sputum collected Other Died Unknown New Address: Phone #: In state, out of jurisdiction (enter city/county) Specify Specify Out of state (enter state) Specify Specify Out of the U.S. (enter country) Specify Specify If moved out of the U.S., transnational referral? (select one) No Yes 43. Date Therapy Stopped: 44. Reason Therapy Stopped or Never Started (select one) Completed therapy Not TB If Died, Indicate Cause of Death: (select one) Lost Died Related to TB disease Unrelated to TB disease Uncooperative or refused Other Related to TB therapy Unknown Adverse treatment event Unknown SEP 15 Page 5

45. Reason Therapy Extended >12 Months: (select all that apply) Rifampin resistance Non-adherence Clinically indicated other reasons Adverse drug reaction Failure Other (specify) 46. Type of Outpatient Health Care Provider: (select all that apply) Local/State Health Department IHS, Tribal HD, or Tribal Corp. Inpatient care only Unknown Private Outpatient Institutional/Correctional Other 47. Directly Observed Therapy (DOT): (select one) Follow up 2 No, Totally Self Administered Yes, Totally Directly Observed Yes, Both Directly Observed and Self Administered Unknown Number of Weeks of Directly Observed Therapy (DOT): 48. Follow-up Drug Susceptibility Testing: Was follow-up drug susceptibility testing done? If No or Unknown, do not complete the rest of the form. If Yes: Enter date last isolate collected for which drug susceptibility testing was done: Enter specimen type: Sputum OR if not sputum, specify: 49. Last (Final) Drug Susceptibility Results (select one option for each drug) Isoniazid Capreomycin Rifampin Ciprofloxacin Pyrazinamide Levofloxacin Ethambutol Ofloxacin Streptomycin Moxifloxacin Rifabutin Other Quinolones Rifapentine Cycloserine Ethionamide PAS Amikacin Gatifloxacin Kanamycin Other drug Other drug Lab: Report prepared by Date: Remarks: Signature: (not legal unless signed) SEP 15 Page 6